BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• Press Releases

  FluoGuide A/S Publishes Interim Report for Q2 2026

  August 25, 2026

   · 

  4 min read
• Press Releases

  New Publication Broadens the Potential of DiviTum TKa in Immuno-Oncology

  August 25, 2026

   · 

  2 min read
• Press Releases

  Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease

  August 25, 2026

   · 

  6 min read
• 

  Weight loss

  Lilly takes oral obesity race abroad with UK launch of Foundayo

  Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily outcompete Novo Nordisk “given the high margins of a small-molecule therapy,” Truist analyst Srikripa Devarakonda told BioSpace.

  August 25, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• Press Releases

  Astrocyte Pharmaceuticals Receives NIH Award to Evaluate AST-004 in Substance Use Disorders

  August 25, 2026

   · 

  8 min read
• Press Releases

  Innovent Announces 2026 Interim Results and Business Updates

  August 25, 2026

   · 

  12 min read
• Press Releases

  Amplio Spine™ Appoints Nomen Azeem, MD, as Chief Clinical Officer and Founding Chair of the Clinical Advisory Board

  August 25, 2026

   · 

  2 min read
• Press Releases

  Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities

  August 25, 2026

   · 

  2 min read
• 

  Immunology and inflammation

  Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

  While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.

  August 25, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• Press Releases

  Precigen’s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

  August 25, 2026

   · 

  3 min read